Efficacy and Safety of Vonoprazan-Based Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Meta-Analysis

Saishu Dong; Zhenggui Xiong; Dingrong Yang; Tao Liu

doi:10.62177/apjcmr.v1i2.325

Authors

Saishu Dong Tengchong Houqiao Health-Center
Zhenggui Xiong Tengchong People's Hospital
Dingrong Yang Tengchong People's Hospital
Tao Liu Tengchong People's Hospital

DOI:

https://doi.org/10.62177/apjcmr.v1i2.325

Keywords:

Vonoprazan, Helicobacter Pylori, Proton Pump Inhibitor, Quadruple Therapy, Efficacy, Safety

Abstract

Aims: To compare the efficacy and safety of vonoprazan-based bismuth-containing quadruple therapy (VBCQ) versus proton pump inhibitor (PPI)-based bismuth-containing quadruple Therapy (PBCQ) for Helicobacter pylori eradication. Methods: We performed a systematic search in PubMed, Embase, Web of Science, Cochrane Library, CNKI, Wanfang databases for relevant randomized controlled trials up to March 2024. Meta-analysis by RevMan 5.4 software. Results: Ten randomized controlled trials were evaluated in this meta-analysis. In intention-to-treat (ITT) analysis and per-protocol (PP) analysis, the eradication rate of VBCQ was significantly higher than PBCQ [ITT overall eradication rate: 86.7% vs 82.8%, RR: 1.05,95% CI (1.05, 1.09), P < 0.05; PP overall eradication rate: 92.0% vs 88.0%; RR =1.05,95% CI (1.05, 1.08), P < 0.05]. The incidence of adverse events in VBCQ was higher than PBCQ (36.7% vs 36.5%), there was no significant difference (P > 0.05). Conclusions: VBCQ has a higher eradication rate and comparable safety.

Downloads

Download data is not yet available.

References

Ren, S., Cai, P., Liu, Y., et al. (2021). Prevalence of Helicobacter pylori infection in China: A systematic review and meta-analysis. Journal of Gastroenterology and Hepatology, 37(3), 464–470.

Helicobacter pylori Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. (2022). Sixth Chinese national consensus report on the management of Helicobacter pylori infection (treatment excluded). Chinese Journal of Digestion, 42(5), 289–303.

Helicobacter pylori Study Group, Chinese Society of Gastroenterology, Chinese Medical Association. (2022). 2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chinese Journal of Digestion, 42(11), 745–756.

Chen, C., Zhang, D., Huang, S., et al. (2024). Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: A single-center, open-label, non-inferiority, randomized controlled trial. BMC Gastroenterology, 24(1), 131.

Deng, X. J., Wang, Z., Cheng, Z. Y., et al. (2022). Observation of efficacy of a novel potassium-competitive acid blocker vonoprazan in the treatment of H. pylori infection. Chinese Journal of Integrated Traditional and Western Medicine on Digestion, 30(11), 789–793.

Hou, X., Meng, F., Wang, J., et al. (2022). Vonoprazan non-inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients. Journal of Gastroenterology and Hepatology, 37(7), 1275–1283.

Huh, K. Y., Chung, H., Kim, Y. K., et al. (2022). Evaluation of safety and pharmacokinetics of bismuth-containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication. British Journal of Clinical Pharmacology, 88(1), 138–144.

Lian, Y. Q. (2023). *Clinical study of fourfold therapy with vonoprazan fumarate in the treatment of Helicobacter pylori [Master’s thesis, Yichun University].

Li, M. N. (2022). Efficacy and safety of vonoprazan against Helicobacter pylori in the elderly [Master’s thesis, Xi’an Medical University].

Lu, L., Wang, Y., Ye, J., et al. (2023). Quadruple therapy with vonoprazan 20 mg daily as a first-line treatment for Helicobacter pylori infection: A single-center, open-label, noninferiority, randomized controlled trial. Helicobacter, 28(1), e12940.

Miao, J., Hu, C., Tang, J., et al. (2023). Pharmacokinetics, safety, and tolerability of vonoprazan- or esomeprazole-based bismuth-containing quadruple therapy: A Phase 1, double-blind, parallel-group study in adults with Helicobacter pylori infection in China. Clinical Pharmacology in Drug Development, 12(10), 1036–1044.

Ran, L., Liu, L. L., Wang, Y., et al. (2023). Study on the efficacy of vonoprazan in the treatment of Helicobacter pylori. Journal of Modern Medicine and Health, 39(20), 3437–3441, 3448.

Song, Z., Du, Q., Zhang, G., et al. (2022). A randomized, double-blind, phase 3 study to evaluate the efficacy and safety of vonoprazan-based versus esomeprazole-based bismuth-containing quadruple therapy for the eradication of Helicobacter pylori infection in China. United European Gastroenterology Journal, 10, 42.

Han, Y. Y., Guan, J. L., Tian, D. A., et al. (2022). The role and research progress of acid suppressants in Helicobacter pylori infection eradication. Chinese Journal of Digestion, 42(6), 426–429.

Miftahussurur, M., Pratama, P. B., & Yamaoka, Y. (2020). The potential benefits of vonoprazan as Helicobacter pylori infection therapy. Pharmaceuticals (Basel), 13(10), 276.

Laine, L., Sharma, P., Mulford, D. J., et al. (2022). Pharmacodynamics and pharmacokinetics of the potassium-competitive acid blocker vonoprazan and the proton pump inhibitor lansoprazole in US subjects. American Journal of Gastroenterology, 117(7), 1158–1161.

Wang, Y., Du, J., Zhang, D., et al. (2023). Primary antibiotic resistance in Helicobacter pylori in China: A systematic review and meta-analysis. Journal of Global Antimicrobial Resistance, 34, 30–38.

Hong, T. C., El-Omar, E. M., Kuo, Y. T., et al. (2024). Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: An updated systematic review and meta-analysis. Lancet Gastroenterology & Hepatology, 9(1), 56–67.

Malfertheiner, P., Megraud, F., Rokkas, T., et al. (2022). Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut, 71, 1724–1762.

Chey, W. D., Howden, C. W., Moss, S. F., et al. (2024). ACG clinical guideline: Treatment of Helicobacter pylori infection. American Journal of Gastroenterology, 119(9), 1730–1753.

Liu, T., Zheng, S., Yang, J., et al. (2024). Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori eradication: A meta-analysis. Journal of Hainan Medical University, 30(16), 1259–1265.